ALICIA DEMITCHELL: Open Payments
NPI 1588414494 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$537 in 28 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $376 · 2025 $537
Food & beverage: $537
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $172 |
| Astellas Pharma US Inc | 4 | $66 |
| ABBVIE INC. | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Echosens North America, Inc. | 1 | $34 |
| PFIZER INC. | 2 | $32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
Products named: Ozempic, Veozah, Wegovy, QULIPTA, Fibroscan, AIRSUPRA, XIFAXAN, JARDIANCE.
Industry payments across TX — which companies pay providers there.
